United States

Mediwound Ltd (MDWD.OQ)

MDWD.OQ on NASDAQ Stock Exchange Global Market

1:38pm EDT
Change (% chg)

$-0.10 (-1.82%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low

Chart for


MediWound Ltd. is a biopharmaceutical company. The Company focuses on developing, manufacturing and commercializing therapeutics products in the fields of severe burns, chronic and other hard-to-heal wounds, connective tissue disorders and other indications. The Company's product, NexoBrid, is indicated for the removal of dead... (more)


Beta: 0.04
Market Cap(Mil.): $148.76
Shares Outstanding(Mil.): 27.05
Dividend: --
Yield (%): --


  MDWD.OQ Industry Sector
P/E (TTM): -- 29.23 32.47
EPS (TTM): -0.64 -- --
ROI: -42.07 13.79 13.34
ROE: -167.14 15.58 15.26

BRIEF-MediWound Q3 loss per share $0.49

* Q3 earnings per share view $-0.19 -- Thomson Reuters I/B/E/S

Nov 16 2017

BRIEF-Tel Aviv district court ordered Mediwound to purchase about $1.5 mln of PolyHeal shares

* Tel Aviv district court ordered Mediwound to purchase approximately $1.5 million of PolyHeal shares; Mediwound weighing an appeal

Nov 13 2017

BRIEF-MediWound appoints Mr. Stephen T. Wills as chairman

* MediWound appoints Mr. Stephen T. Wills as chairman to its Board of Directors

Oct 25 2017

BRIEF-MediWound Ltd announces new distribution agreement with Holy Stone Healthcare for NexoBrid

* MediWound Ltd - ‍ announced an agreement with Holy Stone Healthcare, co for distribution of Nexobrid in Taiwan for treatment of severe burns​ Source text for Eikon: Further company coverage:

Oct 16 2017

Earnings vs. Estimates